JP2014527072A5 - - Google Patents

Download PDF

Info

Publication number
JP2014527072A5
JP2014527072A5 JP2014529962A JP2014529962A JP2014527072A5 JP 2014527072 A5 JP2014527072 A5 JP 2014527072A5 JP 2014529962 A JP2014529962 A JP 2014529962A JP 2014529962 A JP2014529962 A JP 2014529962A JP 2014527072 A5 JP2014527072 A5 JP 2014527072A5
Authority
JP
Japan
Prior art keywords
core protein
seq
concentration
amino acid
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014529962A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014527072A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/054534 external-priority patent/WO2013036973A2/en
Publication of JP2014527072A publication Critical patent/JP2014527072A/ja
Publication of JP2014527072A5 publication Critical patent/JP2014527072A5/ja
Pending legal-status Critical Current

Links

JP2014529962A 2011-09-09 2012-09-10 ウイルスタンパク質の集合を制御するための方法および組成物 Pending JP2014527072A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161532986P 2011-09-09 2011-09-09
US61/532,986 2011-09-09
PCT/US2012/054534 WO2013036973A2 (en) 2011-09-09 2012-09-10 Methods and compositions for controlling assembly of viral proteins

Publications (2)

Publication Number Publication Date
JP2014527072A JP2014527072A (ja) 2014-10-09
JP2014527072A5 true JP2014527072A5 (enExample) 2015-11-05

Family

ID=47832822

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014529962A Pending JP2014527072A (ja) 2011-09-09 2012-09-10 ウイルスタンパク質の集合を制御するための方法および組成物

Country Status (6)

Country Link
US (2) US8865188B2 (enExample)
EP (1) EP2747774A4 (enExample)
JP (1) JP2014527072A (enExample)
AU (1) AU2012305714A1 (enExample)
CA (1) CA2847888A1 (enExample)
WO (1) WO2013036973A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010120874A2 (en) 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
CA2847888A1 (en) 2011-09-09 2013-03-14 Biomed Realty, L.P. Methods and compositions for controlling assembly of viral proteins
CA2936092A1 (en) * 2013-01-23 2014-07-31 The Board Of Trustees Of The Leland Stanford Junior University Stabilized hepatitis b core polypeptide
GB201506870D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
CN106279379B (zh) * 2016-09-13 2020-05-22 华兰生物工程股份有限公司 一种免疫原HM4-M2e及其制备方法与应用
TWI634899B (zh) * 2016-11-22 2018-09-11 國立臺灣大學 包含類b肝病毒顆粒作為佐劑的疫苗組成物
CN107488217A (zh) * 2017-09-13 2017-12-19 华兰生物疫苗有限公司 一种多肽、免疫原性偶联物和流感疫苗
GB201716254D0 (en) * 2017-10-05 2017-11-22 Univ Leuven Kath Live-attenuated flaviruses with heterologous antigens
KR20210077711A (ko) * 2018-10-12 2021-06-25 고쿠리쓰 겐큐 가이하쓰 호징 리가가쿠 겐큐소 B형 간염 바이러스 복제 저해제 및 그것을 포함하는 b형 간염 치료용 의약 조성물
CN113508125A (zh) * 2018-12-28 2021-10-15 小利兰·斯坦福大学托管委员会 工程化乙型肝炎核心多肽
CN110125434B (zh) * 2019-05-14 2022-07-29 东南大学 一种光热金纳米材料的制备方法
EP4103588A1 (en) * 2020-02-13 2022-12-21 The Trustees of Indiana University Hepadnavirus capsid protein heterodimers and virus-like particles
GB202210507D0 (en) * 2022-07-18 2022-08-31 Univ Dundee Virus-like particles, heterodimeric capsid proteins and methods of production thereof

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816564A (en) 1986-01-31 1989-03-28 Merck & Co., Inc. Method for producing hepatitis B virus proteins in yeast
IL90161A0 (en) 1988-05-13 1989-12-15 Phillips Petroleum Co Expression of hepatitis b s and pres2 proteins in methylotrophic yeasts
US5620689A (en) 1989-10-20 1997-04-15 Sequus Pharmaceuuticals, Inc. Liposomes for treatment of B-cell and T-cell disorders
EP0652967B1 (en) 1990-08-15 1998-02-04 Therion Biologics Corporation Self-assembling replication defective hybrid virus particles
WO1993000103A1 (en) 1991-06-21 1993-01-07 The Wistar Institute Of Anatomy And Biology Chimeric envelope proteins for viral targeting
NZ262679A (en) 1993-02-22 1997-08-22 Vivorx Pharmaceuticals Inc Compositions for in vivo delivery of pharmaceutical agents where the agents are contained in a polymeric shell
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
EP0804249A2 (en) 1994-03-15 1997-11-05 Brown University Research Foundation Polymeric gene delivery system
WO1995032706A1 (en) 1994-05-31 1995-12-07 Inex Pharmaceuticals Corp. Virosome-mediated intracellular delivery of therapeutic agents
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US6613749B1 (en) 1994-07-26 2003-09-02 Imperial College Innovations Limited Papovavirus pseudocapsids and use thereof for exogenous material transfer
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
IL160406A0 (en) 1995-06-15 2004-07-25 Crucell Holland Bv A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products
EE9800160A (et) 1995-11-28 1998-12-15 Genvec, Inc. Vektorid ja meetodid geenide ülekandmiseks rakkudesse
US6284494B1 (en) 1995-12-12 2001-09-04 The University Of British Columbia Methods and compositions for synthesis of oligosaccharides using mutant glycosidase enzymes
US6063370A (en) 1996-04-05 2000-05-16 The Board Of Trustees Of The University Of Illinois Macromolecular complexes for drug delivery
FR2749323B1 (fr) 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique
US5980901A (en) 1996-09-18 1999-11-09 The Board Of Regents Of The University Of Texas System Viral defective interfering particles and uses thereof
CA2269097C (en) 1996-11-08 2007-01-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Synthesis and purification of hepatitis c virus-like particles
US6180389B1 (en) 1997-01-03 2001-01-30 The Research And Development Institute, Inc. Virion-constrained nanoparticles comprising a plant virion coat protein shell and encapsulated guest molecules
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6287857B1 (en) 1998-02-09 2001-09-11 Genzyme Corporation Nucleic acid delivery vehicles
AU2662999A (en) 1998-02-09 1999-08-23 Genzyme Corporation Nucleic acid delivery vehicles
CZ302092B6 (cs) 1998-02-12 2010-10-06 Immune Complex, Corporation Konjugát upraveného jaderného proteinu hepatitidy B, jeho cástice, inokulum a zpusob indukce protilátek
KR100651113B1 (ko) 1998-08-05 2006-11-30 소니 가부시끼 가이샤 전해질용 조성물, 전해질 및 그의 제조 방법 및 그것을이용한 전지
WO2000009158A1 (en) 1998-08-12 2000-02-24 University Of Virginia Patent Foundation Assay for assembly of herpes simplex virus capsid
US6759237B1 (en) 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
EP1845163A3 (en) 1998-11-05 2007-10-31 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype l nucleic acid sequences, vetors and host cells containing same
TR200102423T2 (tr) 1998-12-04 2002-02-21 Biogen, Inc. Peptid ligandları yoluyla bağlı birden fazla imünojenik bileşeni olan HBV çekirdek antijeni parçacıkları
US6710173B1 (en) 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
WO2001002551A2 (en) 1999-06-30 2001-01-11 Evotec Oai Ag Virus like particles, preparation and use in screening and functional genomics
US20020064520A1 (en) 1999-08-19 2002-05-30 Yanina Rozenberg Targeted artificial gene delivery
US6593308B2 (en) 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
US6602932B2 (en) 1999-12-15 2003-08-05 North Carolina State University Nanoparticle composites and nanocapsules for guest encapsulation and methods for synthesizing same
GB9930533D0 (en) 1999-12-23 2000-02-16 Mitsubishi Tokyo Pharm Inc Nucleic acid delivery
US6616944B2 (en) 2000-03-08 2003-09-09 Medinnova Gesellschaft Fur Medizinsche Innovationen Aus Adkademischer Forschung Mbh Self-assembling colloidal carriers for protein delivery
US7332337B2 (en) 2000-05-16 2008-02-19 Galapagos Nv Viral vectors having tissue tropism for T-lymphocytes, B- and mast cells
IL153831A0 (en) 2000-07-19 2003-07-31 Univ California Methods for therapy of neurodegenerative disease of the brain
US6696038B1 (en) 2000-09-14 2004-02-24 Expression Genetics, Inc. Cationic lipopolymer as biocompatible gene delivery agent
CA2429814C (en) 2000-12-01 2014-02-18 Thomas Tuschl Rna interference mediating small rna molecules
WO2002044204A2 (en) 2000-12-01 2002-06-06 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Cell-free assembly of lentiviral capsids
DE60037263T2 (de) 2000-12-29 2008-10-09 Evotec Ag Virus-ähnliche Partikel, ihre Herstellung und ihre Verwendung beim pharmazeutischen Screening und funktionelle Genomanwendungen
EP1409748B1 (en) 2001-06-22 2011-10-26 The Trustees of The University of Pennsylvania Recombinant Adenoviruses comprising simian adenovirus proteins and uses thereof.
US7101995B2 (en) 2001-08-27 2006-09-05 Mirus Bio Corporation Compositions and processes using siRNA, amphipathic compounds and polycations
AU2002335709B8 (en) 2001-09-06 2008-12-18 Cornell Research Foundation, Inc. Human Immunodeficiency Virus Envelope Clycoprotein Mutants and Uses Thereof
US7148343B2 (en) 2001-10-12 2006-12-12 Gentra Systems, Inc. Compositions and methods for using a solid support to purify RNA
AU2002365366B2 (en) 2001-11-21 2007-05-10 The Trustees Of The University Of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
EP1944043A1 (en) 2001-11-21 2008-07-16 The Trustees of the University of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
PT1453547T (pt) 2001-12-17 2016-12-28 Univ Pennsylvania Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas
BR0311995A (pt) 2002-06-20 2005-04-05 Cytos Biotechnology Ag Partìculas semelhantes a vìrus empacotadas para o uso como adjuvantes: método de preparação e uso
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
EP1447079A1 (de) 2003-02-15 2004-08-18 Fraunhofer-Gesellschaft für angewandte Forschung e.V. Vesikel mit chimären Rezeptoren zur Induktion einer gerichteten T-Zellantwort in vivo
EP1585504A4 (en) 2002-11-06 2009-07-15 Azaya Therapeutics Inc Protein stabilized liposomal formulations of pharmaceutical active ingredients
JP2004175665A (ja) 2002-11-22 2004-06-24 Japan Science & Technology Agency タンパク質中空ナノ粒子およびそれを用いた薬剤
CA2509365C (en) 2002-12-09 2012-08-07 American Bioscience, Inc. Compositions and methods of delivery of pharmacological agents
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
JP2007513261A (ja) 2003-10-15 2007-05-24 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム ウイルスファイバー
EP1773303A2 (en) 2004-05-25 2007-04-18 Chimeracore, Inc. Self-assembling nanoparticle drug delivery system
US20080131928A1 (en) 2004-07-01 2008-06-05 Hiroshi Handa Viral Particle-Like Construct and Method of Forming the Same Under Physiological Conditions
GB0416487D0 (en) 2004-07-23 2004-08-25 Isis Innovation Modified virus
CN101056539B (zh) 2004-09-09 2012-12-12 综合医院公司 调节心脏细胞中的磷酸酶活性
US20070248573A1 (en) 2004-09-17 2007-10-25 Joseph Sturino Chimeric Bacteriophages, Chimeric Phage-Like Particles, and Chimeric Phage Ghost Particles, Methods for Their Production and Use
CN2763975Y (zh) 2004-12-11 2006-03-08 鸿富锦精密工业(深圳)有限公司 热管式散热装置
US20090123426A1 (en) 2004-12-17 2009-05-14 Chiang Li Compositions for Bacterial Mediated Gene Silencing and Methods of Using the Same
WO2006088229A1 (ja) 2005-02-16 2006-08-24 The Circle For The Promotion Of Science And Engineering 改変されたウイルスカプシドタンパク質及びその使用
US20070160628A1 (en) * 2005-08-31 2007-07-12 Birkett Ashley J Stabilized virus-like particles and epitope display systems
WO2008037504A1 (en) 2006-09-28 2008-04-03 Cytos Biotechnology Ag Interleukin-1 muteins linked to virus-like particles to treat il-1 associated diseases
US20070258889A1 (en) 2005-11-09 2007-11-08 Montana State University Novel nanoparticles and use thereof
US20110104051A1 (en) 2006-03-27 2011-05-05 The Regents Of The University Of California Chemically Modified Viral Capsids as Targeted Delivery Vectors for Diagnostic and Therapeutic Agents
CA2648581A1 (en) * 2006-04-07 2008-09-12 Chimeros, Inc. Compositions and methods for treating b- cell malignancies
WO2008027084A2 (en) 2006-04-28 2008-03-06 The Trustees Of The University Of Pennsylvania Modified aav vectors having reduced capsid immunogenicity and use thereof
EP2012822B1 (en) 2006-04-28 2010-01-20 The Trustees of the University of Pennsylvania Modified adenovirus hexon protein and uses thereof
US20090238885A1 (en) 2006-05-22 2009-09-24 Nizo Food Research B.V. Protein encapsulated particles
EP2056794A4 (en) 2006-08-08 2012-12-26 Univ Texas MULTIPLE ADMINISTRATION OF ACTIVE SUBSTANCES
US9803189B2 (en) 2006-08-23 2017-10-31 Stc.Unm Virus-like platform for rapid vaccine discovery
EP2120894A1 (en) 2006-10-25 2009-11-25 Universidade de Coimbra Oral submicron particle delivery system for proteins and process for its production
CA2683063A1 (en) 2007-04-09 2008-10-16 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
CA2597878A1 (en) * 2007-09-13 2009-03-13 Ankegens Laboratories Capsid protein and use therefore
WO2010042751A2 (en) 2008-10-08 2010-04-15 Chimeros Inc. Chimeric therapeutics, compositions, and methods for using same
WO2010042749A2 (en) 2008-10-08 2010-04-15 Chimeros Inc. Chimeric therapeutics, compositions, and methods for using same
WO2010042743A2 (en) * 2008-10-08 2010-04-15 Chimeros Inc. Chimeric multiplexes, compositions, and methods for using same
WO2010042755A2 (en) 2008-10-08 2010-04-15 Chimeros Inc. Chimeric therapeutics, compositions, and methods for using same
WO2010120874A2 (en) 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
CA2847888A1 (en) 2011-09-09 2013-03-14 Biomed Realty, L.P. Methods and compositions for controlling assembly of viral proteins

Similar Documents

Publication Publication Date Title
JP2014527072A5 (enExample)
JP7219258B2 (ja) ペプチド模倣大環状分子およびその製剤
Ruigrok et al. Studies on the structure of the influenza virus haemagglutinin at the pH of membrane fusion
JP2023018073A5 (enExample)
Blokhina et al. A molecular assembly system for presentation of antigens on the surface of HBc virus-like particles
JP2016052315A5 (enExample)
JP2019194251A5 (enExample)
Hemantha et al. Total chemical synthesis of polypeptides and proteins: chemistry of ligation techniques and beyond
JP2009521908A5 (enExample)
JP2014510518A5 (enExample)
NZ597804A (en) Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein
JP2018532725A5 (enExample)
JP2012095652A5 (enExample)
JP2013520426A5 (enExample)
US20120009212A1 (en) Conjugates utilizing platform technology for stimulating immune response
CN115443288A (zh) 一种免疫球蛋白降解酶IdeE的突变体
WO2009025759A8 (en) Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof
Skehel et al. Influenza haemagglutinin
RU2008146997A (ru) Способ блокирования заражения флавивирусами молекулы и применения
JP2015517464A5 (enExample)
Bereszczak et al. Assessment of differences in the conformational flexibility of hepatitis B virus core‐antigen and e‐antigen by hydrogen deuterium exchange‐mass spectrometry
RU2015140603A (ru) Вакцины на основе нуклеопротеина вируса гриппа
JP2024513126A5 (enExample)
CN103755810B (zh) 一种长效hiv‐1膜融合抑制剂
MY157396A (en) Novel fusion proteins and use thereof for preparing hepatitis c vaccines